Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program
Shots: Accent to receive ~$446M including up front, pre-clinical, clinical, regulatory, and sales-based milestone along with royalties Ipsen obtains an exclusive license to develop, manufacture […]